Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lupin Pharmaceuticals, a wholly owned US subsidiary of India-based Lupin, has received final approval for the company's abbreviated new drug application for levetiracetam tablets 250mg, 500mg, 750mg and 1000mg from the FDA. Commercial shipments of the product have commenced.
Subscribe to our email newsletter
Lupin’s levetiracetam tablets are the AB-rated generic equivalent of UCB Pharmaceuticals’s Keppra tablets, indicated as adjunctive therapy in the treatment of certain types of seizures associated with epilepsy.